Retention of Participant and Study Partner Dyads in Alzheimer’s Disease Clinical Trials

Study retention is crucial to clinical trial success. Greater than expected dropout rates can lead to reduced power and biased results. Alzheimer’s disease (AD) trial success depends not only on participants but also on their study partners. We investigated whether study partner type was associated with the risk of dropout in large Phase 3 registration trials.